Monday, May 14, 2007
omeprazol
COX-2 Inhibitor plus PPI Reduces Bleeding in High-Risk Patients
Adding a proton-pump inhibitor to celecoxib treatment in patients at very high risk for ulcer bleeds greatly reduces the incidence of bleeding, according to a Lancet report.
Some 270 patients taking nonselective NSAIDS for arthritis and presenting with upper-GI bleeding underwent randomization — after their ulcers had healed — to treatment with either celecoxib (200 mg twice daily) plus esomeprazole (20 mg twice daily), or celecoxib alone, for a year. The 13-month incidence of recurrent ulcer bleeding was 0% in the combination-therapy group and 8.9% in the controls.
Commentators write that "the finding provides clear guidance for those individuals at greatest gastrointestinal risk who require an NSAID." They add that the new gastrointestinal data should not be interpreted "without careful consideration of competing risks from the cardiovascular perspective."
L
Adding a proton-pump inhibitor to celecoxib treatment in patients at very high risk for ulcer bleeds greatly reduces the incidence of bleeding, according to a Lancet report.
Some 270 patients taking nonselective NSAIDS for arthritis and presenting with upper-GI bleeding underwent randomization — after their ulcers had healed — to treatment with either celecoxib (200 mg twice daily) plus esomeprazole (20 mg twice daily), or celecoxib alone, for a year. The 13-month incidence of recurrent ulcer bleeding was 0% in the combination-therapy group and 8.9% in the controls.
Commentators write that "the finding provides clear guidance for those individuals at greatest gastrointestinal risk who require an NSAID." They add that the new gastrointestinal data should not be interpreted "without careful consideration of competing risks from the cardiovascular perspective."
L
# posted by roodbont @ 3:22 PM 
